Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced 25 presentations during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. This includes 21 podium presentations and four poster presentations, with highlights on the new StableVisc™ device and the LOTEMAX® ophthalmic gel. Bausch + Lomb will also sponsor two educational events focusing on dry eye disease and the IC-8 Apthera lens. Approximately 18 million Americans are affected by dry eye disease, emphasizing the significance of the topics discussed. Notably, new data from the ARMOR study will be presented, aiming to address antibiotic resistance in ocular microorganisms.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) held its 2023 annual meeting on April 24, 2023, where shareholders elected 10 directors. Key voting results included:
- Nathalie Bernier: 344,100,848 votes for, 124,733 against
- Richard U. De Schutter: 344,094,979 votes for, 130,602 against
- Gary Hu: 344,016,782 votes for, 208,799 against
- Brett Icahn: 344,072,707 votes for, 152,874 against
In addition to the elections, shareholders approved the advisory compensation of executives, an amendment to increase shares under the 2022 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent accounting firm until the 2024 annual meeting. The results will be filed with the SEC.